Biologic therapies for non-hodgkin lymphoma and hodgkin disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are B-cell malignancies that together account for an estimated 75,000 new cases in the United States annually. Many patients with these diseases are successfully treated with cytotoxic therapy; however, the addition of biologic therapy in the form of the anti-CD20 antibody rituximab has significantly improved the outcome of patients, particularly those with B-cell NHL. The success of this agent has led to the development of multiple other monoclonal antibodies directed at targets on lymphoma cells and these therapies are now in clinical trials to determine their utility in the treatment of patients with NHL and HL.

Original languageEnglish (US)
Title of host publicationEmerging Protein Biotherapeutics
PublisherCRC Press
Pages223-245
Number of pages23
ISBN (Electronic)9781420063219
ISBN (Print)1420063200, 9781420063202
StatePublished - Jan 1 2009

Fingerprint

Biological Therapy
Hodgkin Disease
Non-Hodgkin's Lymphoma
Cells
Monoclonal Antibodies
B-Cell Lymphoma
Cell- and Tissue-Based Therapy
Anti-Idiotypic Antibodies
Lymphoma
B-Lymphocytes
Clinical Trials
Therapeutics
Neoplasms
Rituximab

Keywords

  • Hodgkin’s disease
  • Monoclonal antibody
  • Non-hodgkin lymphoma

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ansell, S. M. (2009). Biologic therapies for non-hodgkin lymphoma and hodgkin disease. In Emerging Protein Biotherapeutics (pp. 223-245). CRC Press.

Biologic therapies for non-hodgkin lymphoma and hodgkin disease. / Ansell, Stephen Maxted.

Emerging Protein Biotherapeutics. CRC Press, 2009. p. 223-245.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ansell, SM 2009, Biologic therapies for non-hodgkin lymphoma and hodgkin disease. in Emerging Protein Biotherapeutics. CRC Press, pp. 223-245.
Ansell SM. Biologic therapies for non-hodgkin lymphoma and hodgkin disease. In Emerging Protein Biotherapeutics. CRC Press. 2009. p. 223-245
Ansell, Stephen Maxted. / Biologic therapies for non-hodgkin lymphoma and hodgkin disease. Emerging Protein Biotherapeutics. CRC Press, 2009. pp. 223-245
@inbook{3d14bab8755b44fea2aab09c08dc3f0f,
title = "Biologic therapies for non-hodgkin lymphoma and hodgkin disease",
abstract = "Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are B-cell malignancies that together account for an estimated 75,000 new cases in the United States annually. Many patients with these diseases are successfully treated with cytotoxic therapy; however, the addition of biologic therapy in the form of the anti-CD20 antibody rituximab has significantly improved the outcome of patients, particularly those with B-cell NHL. The success of this agent has led to the development of multiple other monoclonal antibodies directed at targets on lymphoma cells and these therapies are now in clinical trials to determine their utility in the treatment of patients with NHL and HL.",
keywords = "Hodgkin’s disease, Monoclonal antibody, Non-hodgkin lymphoma",
author = "Ansell, {Stephen Maxted}",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
isbn = "1420063200",
pages = "223--245",
booktitle = "Emerging Protein Biotherapeutics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Biologic therapies for non-hodgkin lymphoma and hodgkin disease

AU - Ansell, Stephen Maxted

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are B-cell malignancies that together account for an estimated 75,000 new cases in the United States annually. Many patients with these diseases are successfully treated with cytotoxic therapy; however, the addition of biologic therapy in the form of the anti-CD20 antibody rituximab has significantly improved the outcome of patients, particularly those with B-cell NHL. The success of this agent has led to the development of multiple other monoclonal antibodies directed at targets on lymphoma cells and these therapies are now in clinical trials to determine their utility in the treatment of patients with NHL and HL.

AB - Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are B-cell malignancies that together account for an estimated 75,000 new cases in the United States annually. Many patients with these diseases are successfully treated with cytotoxic therapy; however, the addition of biologic therapy in the form of the anti-CD20 antibody rituximab has significantly improved the outcome of patients, particularly those with B-cell NHL. The success of this agent has led to the development of multiple other monoclonal antibodies directed at targets on lymphoma cells and these therapies are now in clinical trials to determine their utility in the treatment of patients with NHL and HL.

KW - Hodgkin’s disease

KW - Monoclonal antibody

KW - Non-hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85057500904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057500904&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057500904

SN - 1420063200

SN - 9781420063202

SP - 223

EP - 245

BT - Emerging Protein Biotherapeutics

PB - CRC Press

ER -